Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
April 17 2024 - 7:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
for indications in virology and immunology, today announced that
data from the company’s SPRINT (SARS-Cov-2 PRotease
INhibitor Treatment) study of EDP-235 has been
accepted for a poster presentation at ESCMID Global 2024 (formerly
ECCMID) being held April 27–30 in Barcelona, Spain.
The poster presentation includes primary and post-hoc analyses
from the double-blind, placebo-controlled Phase 2 clinical trial of
EDP-235, a 3CL protease inhibitor, in non-hospitalized, symptomatic
adults with mild or moderate COVID-19 who were not at high risk for
severe disease.
Poster Title: “Efficacy and Safety of EDP-235 in
Non-Hospitalized Adults with Mild or Moderate COVID-19: Results
from the Phase 2 SPRINT Study” Abstract Number: 02980
Poster Number: PO423 Day: April 27, 2024 Time:
12:00 p.m. CEST / 6:00 a.m. ET Session Location: Poster Area
Session Title: COVID-19 (incl virology, epidemiology,
evolution, immune response, diagnosis, treatment, vaccination,
prevention, response and societal impact) Presenter: Scott
T. Rottinghaus, M.D., Chief Medical Officer, Enanta
Pharmaceuticals, Inc.
The scientific program for ESCMID Global 2024 can be found at
https://www.eccmid.org/scientific-programme
About Enanta Pharmaceuticals, Inc. Enanta is using its
robust, chemistry-driven approach and drug discovery capabilities
to become a leader in the discovery and development of small
molecule drugs with an emphasis on indications in virology and
immunology. Enanta’s research and development programs are
currently focused on respiratory syncytial virus (RSV) and chronic
spontaneous urticaria (CSU) and the company has previously advanced
clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic
hepatitis B virus (HBV) infection.
Glecaprevir, a protease inhibitor discovered by Enanta, is part
of one of the leading treatment regimens for curing chronic
hepatitis C virus infection (HCV) and is sold by AbbVie in numerous
countries under the trade names MAVYRET®(U.S.) and
MAVIRET®(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie contribute ongoing funding to Enanta’s
operations. Please visit http://www.enanta.com for more
information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240417219973/en/
Media and Investors Contact Jennifer Viera
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2023 to Apr 2024